JP2021514185A - Ｔ細胞系列の細胞を発生させるための方法 - Google Patents

Ｔ細胞系列の細胞を発生させるための方法 Download PDF

Info

Publication number
JP2021514185A
JP2021514185A JP2020543276A JP2020543276A JP2021514185A JP 2021514185 A JP2021514185 A JP 2021514185A JP 2020543276 A JP2020543276 A JP 2020543276A JP 2020543276 A JP2020543276 A JP 2020543276A JP 2021514185 A JP2021514185 A JP 2021514185A
Authority
JP
Japan
Prior art keywords
cells
cell
notch ligand
primordial
beads
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020543276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514185A5 (cg-RX-API-DMAC7.html
Inventor
ジュアン カルロス スニガ−プフルッカー
ジュアン カルロス スニガ−プフルッカー
マフムード モータシャミ
マフムード モータシャミ
アシュトン トロットマン−グラント
アシュトン トロットマン−グラント
Original Assignee
サニーブルック リサーチ インスティチュート
サニーブルック リサーチ インスティチュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サニーブルック リサーチ インスティチュート, サニーブルック リサーチ インスティチュート filed Critical サニーブルック リサーチ インスティチュート
Publication of JP2021514185A publication Critical patent/JP2021514185A/ja
Publication of JP2021514185A5 publication Critical patent/JP2021514185A5/ja
Priority to JP2023191915A priority Critical patent/JP7866537B2/ja
Priority to JP2025216743A priority patent/JP2026031647A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C12N5/0075—General culture methods using substrates using microcarriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2020543276A 2018-02-14 2019-02-14 Ｔ細胞系列の細胞を発生させるための方法 Pending JP2021514185A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023191915A JP7866537B2 (ja) 2018-02-14 2023-11-10 Ｔ細胞系列の細胞を発生させるための方法
JP2025216743A JP2026031647A (ja) 2018-02-14 2025-12-02 Ｔ細胞系列の細胞を発生させるための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862630497P 2018-02-14 2018-02-14
US62/630,497 2018-02-14
PCT/CA2019/050181 WO2019157597A1 (en) 2018-02-14 2019-02-14 Method for generating cells of the t cell lineage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023191915A Division JP7866537B2 (ja) 2018-02-14 2023-11-10 Ｔ細胞系列の細胞を発生させるための方法

Publications (2)

Publication Number Publication Date
JP2021514185A true JP2021514185A (ja) 2021-06-10
JP2021514185A5 JP2021514185A5 (cg-RX-API-DMAC7.html) 2022-02-10

Family

ID=67619677

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020543276A Pending JP2021514185A (ja) 2018-02-14 2019-02-14 Ｔ細胞系列の細胞を発生させるための方法
JP2023191915A Active JP7866537B2 (ja) 2018-02-14 2023-11-10 Ｔ細胞系列の細胞を発生させるための方法
JP2025216743A Pending JP2026031647A (ja) 2018-02-14 2025-12-02 Ｔ細胞系列の細胞を発生させるための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023191915A Active JP7866537B2 (ja) 2018-02-14 2023-11-10 Ｔ細胞系列の細胞を発生させるための方法
JP2025216743A Pending JP2026031647A (ja) 2018-02-14 2025-12-02 Ｔ細胞系列の細胞を発生させるための方法

Country Status (8)

Country Link
US (2) US12467034B2 (cg-RX-API-DMAC7.html)
EP (1) EP3752602A4 (cg-RX-API-DMAC7.html)
JP (3) JP2021514185A (cg-RX-API-DMAC7.html)
KR (1) KR20200121817A (cg-RX-API-DMAC7.html)
CN (1) CN112041431A (cg-RX-API-DMAC7.html)
AU (2) AU2019220935B2 (cg-RX-API-DMAC7.html)
CA (1) CA3091158A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019157597A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3091158A1 (en) 2018-02-14 2019-08-22 Sunnybrook Research Institute Method for generating cells of the t cell lineage
EP4237542A1 (en) * 2020-10-28 2023-09-06 Sangamo Therapeutics, Inc. Generation of cd4+ effector and regulatory t cells from human pluripotent stem cells
AU2021386370A1 (en) 2020-11-24 2023-06-22 Lyell Immunopharma, Inc. Methods for making, compositions comprising, and methods of using rejuvenated t cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
EP4289940A4 (en) * 2021-02-05 2025-02-26 National University Corporation Kobe University ?? T-CELLS FROM INDUCED PLURIPOTENT STEM CELLS AND PRODUCTION PROCESSES THEREFOR
AU2022253223A1 (en) 2021-04-07 2023-09-28 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
CA3210702A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Gene transfer vectors and methods of engineering cells
WO2022241558A1 (en) * 2021-05-18 2022-11-24 The University Of British Columbia A method for producing blood progenitor and progenitor t cells, resulting cells and methods and uses thereof
WO2023129937A1 (en) 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
IL314801A (en) 2022-02-22 2024-10-01 Juno Therapeutics Inc Proteinase 3 (PR3) Chimeric Autoantigen Receptor T Cells and Related Methods and Uses
JP2025515095A (ja) 2022-05-04 2025-05-13 センチュリー セラピューティクス，インコーポレイテッド Ｈｌａ－ｅおよびｈｌａ－ｇ導入遺伝子を用いて操作された細胞
US20250090582A1 (en) 2022-06-08 2025-03-20 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
EP4536814A1 (en) 2022-06-08 2025-04-16 Century Therapeutics, Inc. Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof
CN119630695A (zh) 2022-06-08 2025-03-14 世纪治疗股份有限公司 表达cd16变体和nkg2d的遗传工程化细胞及其用途
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
CN120435498A (zh) 2022-11-10 2025-08-05 世纪治疗股份有限公司 具有抗-nectin4嵌合抗原受体的基因工程化细胞及其用途
KR20250150555A (ko) * 2023-01-27 2025-10-20 노치 테라퓨틱스 (캐나다) 인크. 줄기세포/전구세포로부터 t 세포 계통 모집단을 생성하는 방법
WO2025101938A2 (en) 2023-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
WO2025106626A1 (en) 2023-11-15 2025-05-22 Century Therapeutics, Inc. Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
WO2025207795A1 (en) 2024-03-26 2025-10-02 Juno Therapeutics, Inc. Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof
WO2025207798A1 (en) 2024-03-26 2025-10-02 Century Therapeutics, Inc. Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof
US20250332260A1 (en) 2024-04-10 2025-10-30 Garuda Therapeutics, Inc. Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations
US20260083778A1 (en) * 2024-09-20 2026-03-26 Boston Medical Center Corporation Generation of cd4 t cells

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506322A (ja) * 2002-04-05 2006-02-23 ロランティス リミテッド 内科療法
JP2006517533A (ja) * 2003-01-23 2006-07-27 ロランティス リミテッド Ｎｏｔｃｈシグナル伝達経路のアクチベーターを用いる自己免疫疾患の治療
WO2007027226A2 (en) * 2005-04-28 2007-03-08 Board Of Regents, The University Of Texas System Systems and methods for the production of differentiated cells
WO2016123100A1 (en) * 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2017173551A1 (en) * 2016-04-08 2017-10-12 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same
JP2017531148A (ja) * 2014-09-16 2017-10-19 ヒタチ ゾウセン イノバ アクチェンゲゼルシャフト 廃棄物焼却プラントの燃焼チャンバー内で発生するスラグを処理するための方法及び装置

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201043699A (en) 2002-03-25 2010-12-16 Takara Bio Inc Process for producing cytotoxic lymphocyte
US7575925B2 (en) * 2002-12-10 2009-08-18 Sunnybrook Health Sciences Centre Cell preparations comprising cells of the T cell lineage and methods of making and using them
EP2321407A4 (en) 2008-09-11 2012-07-18 Univ Florida SYSTEM AND METHOD FOR THE PRODUCTION OF T-CELLS
US8772028B2 (en) * 2008-11-07 2014-07-08 Sunnybrook Health Sciences Centre CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using
US8871510B2 (en) 2009-12-03 2014-10-28 University Of Utah Research Foundation Methods for generating T lymphocytes from hematopoietic stem cells
PL2539441T3 (pl) 2010-02-22 2017-06-30 Université Pierre Et Marie Curie (Paris 6) Podłoże do hodowli komórkowej do wzrostu i różnicowania komórek linii hematopoetycznych
US9834754B2 (en) 2011-11-21 2017-12-05 University Health Network Populations of hematopoietic progenitors and methods of enriching stem cells therefor
FR3026744B1 (fr) 2014-10-06 2024-04-19 Hopitaux Paris Assist Publique Methode de generation de progeniteurs de cellules t
WO2016187459A1 (en) 2015-05-20 2016-11-24 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
US20190134169A1 (en) 2016-04-26 2019-05-09 Temple University-Of The Commonwealth System Of Higher Education DLL4-expressing cells and vaccine using the same
ES2931530T3 (es) 2017-02-13 2022-12-30 Hopitaux Paris Assist Publique Método para generar progenitores de células T
CA3091158A1 (en) 2018-02-14 2019-08-22 Sunnybrook Research Institute Method for generating cells of the t cell lineage
EP4326856A4 (en) 2021-04-23 2025-10-08 Sunnybrook Res Inst STEM CELLS COMPRISING AN UNREARRANGED T CELL RECEPTOR (TCR) GENE LOCUS AND METHODS OF USE THEREOF
WO2022241558A1 (en) 2021-05-18 2022-11-24 The University Of British Columbia A method for producing blood progenitor and progenitor t cells, resulting cells and methods and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506322A (ja) * 2002-04-05 2006-02-23 ロランティス リミテッド 内科療法
JP2006517533A (ja) * 2003-01-23 2006-07-27 ロランティス リミテッド Ｎｏｔｃｈシグナル伝達経路のアクチベーターを用いる自己免疫疾患の治療
WO2007027226A2 (en) * 2005-04-28 2007-03-08 Board Of Regents, The University Of Texas System Systems and methods for the production of differentiated cells
JP2017531148A (ja) * 2014-09-16 2017-10-19 ヒタチ ゾウセン イノバ アクチェンゲゼルシャフト 廃棄物焼却プラントの燃焼チャンバー内で発生するスラグを処理するための方法及び装置
WO2016123100A1 (en) * 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2017173551A1 (en) * 2016-04-08 2017-10-12 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, vol. 79, no. 3, JPN6022055844, 2006, pages 689 - 697, ISSN: 0005102815 *

Also Published As

Publication number Publication date
EP3752602A1 (en) 2020-12-23
CN112041431A (zh) 2020-12-04
JP2024016217A (ja) 2024-02-06
US20200399599A1 (en) 2020-12-24
AU2025204516A1 (en) 2025-07-03
AU2019220935B2 (en) 2025-03-20
JP2026031647A (ja) 2026-02-24
WO2019157597A1 (en) 2019-08-22
US20260043003A1 (en) 2026-02-12
US12467034B2 (en) 2025-11-11
EP3752602A4 (en) 2021-11-24
CA3091158A1 (en) 2019-08-22
KR20200121817A (ko) 2020-10-26
JP7866537B2 (ja) 2026-05-27
AU2019220935A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
US20260043003A1 (en) Method for generating cells of the t cell lineage
JP7181910B2 (ja) 養子療法用の免疫細胞集団を単離、培養、および遺伝子操作するための方法
Larochelle et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy
JP2022033812A (ja) 幹細胞からｔ細胞を作製する方法および該ｔ細胞を用いた免疫療法的方法
CN110506110B (zh) 产生t细胞祖细胞的方法
US8383404B2 (en) Hematopoietic stem cell identification and isolation
JP2010042011A (ja) ヒト胚性幹細胞の造血分化
MXPA06006706A (es) Celulas madre.
US12054743B2 (en) Method for obtaining T cells from pluripotent stem cells, and uses thereof
EP3691660A2 (en) Expansion and use of expanded nk cell fractions
Wang et al. Mouse mesenchymal stem cells can support human hematopoiesis both in vitro and in vivo: the crucial role of neural cell adhesion molecule
US20030100107A1 (en) Compositions and methods for generating differentiated human cells
CN103540566A (zh) 用于长期造血种群恢复的方法和组合物
US20120177618A1 (en) Hematopoietic stromal progenitor cells and uses thereof
WO1998021313A1 (en) Method for culturing hematopoietic stem cells
Kim et al. Generation of CD34+ cells from human embryonic stem cells using a clinically applicable methodology and engraftment in the fetal sheep model
JPWO2005054459A1 (ja) 造血幹細胞あるいは血管内皮前駆細胞の製造方法
US20250090578A1 (en) Method of producing a population of immune cells from pluripotent stem cells
US20140154219A1 (en) Methods and compositions for large-scale isolation of very small embryonic-like (vsel) stem cells
Mizokami et al. Preferential expansion of human umbilical cord blood-derived CD34-positive cells on major histocompatibility complex-matched amnion-derived mesenchymal stem cells
WO2002033043A2 (en) Method and marker for the isolation of human multipotent hematopoietic stem cells
Prasad et al. Propagation and characterisation of dendritic cells from G-CSF mobilised peripheral blood monocytes and stem cells in common marmoset monkeys
RU2797260C2 (ru) Способ получения предшественников т-клеток
Wang et al. ĐFerrata Storti Foundation
Kode et al. Mesenchymal stromal cells and their clinical applications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200930

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230410

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230710